European Urology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
The Oncologist, Journal Year: 2024, Volume and Issue: 29(10), P. 887 - 893
Published: July 16, 2024
Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years. Accurate assessment prognosis in high-risk would aid improving outcomes. Here we evaluate the use circulating tumor DNA (ctDNA) RCC using banked samples and clinical data from a single institution.
Language: Английский
Citations
6
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Feb. 3, 2024
This review comprehensively examines the intricate relationship between carbon monoxide (CO) diffusion capacity and chronic obstructive pulmonary disease (COPD). COPD, comprising bronchitis emphysema, presents a substantial global health burden, necessitating nuanced understanding of function parameters for effective diagnosis management. The delves into physiological underpinnings, measurement techniques, factors influencing CO capacity, emphasizing its pivotal role in assessing alveolar gas exchange efficiency. Key findings elucidate correlations altered severity providing clinicians with valuable insights progression. Considerations age, gender, ethnic disparities normal values highlight importance personalized interpretations. clinical implications extend beyond diagnosis, COPD management prognostication, potential applications predicting treatment response. outlines avenues future research, including advancements technologies exploration novel imaging modalities biomarkers. Ultimately, this serves as foundation refining diagnostic approaches strategies enhancing patient care dynamic landscape COPD.
Language: Английский
Citations
4
The Oncologist, Journal Year: 2024, Volume and Issue: 29(10), P. 821 - 823
Published: Aug. 26, 2024
This commentary focuses on the article by Correa et al association of circulating tumor DNA with patient prognosis in renal cell carcinoma.
Language: Английский
Citations
4
The Oncologist, Journal Year: 2024, Volume and Issue: 29(9), P. 731 - 737
Published: Aug. 2, 2024
In the recent decade, analysis of circulating tumor DNA (ctDNA) has improved cancer care by allowing for rapid detection actionable molecular targets. A new generation tests is now becoming available commercially. These are characterized a superior limit 0.01% vaF or better, radiologically occult residual disease (MRD). MRD have potential to revolutionize neoadjuvant and adjuvant treatment. addition, these can be used as markers assess response. We reviewed current evidence use high-sensitivity assays with particular focus on genitourinary tumors. Multiple studies been reported in urothelial, renal, recently testicular carcinoma. find that sensitivity varies across types setting may reach high 100% urothelial cancer. Specificity tumor-informed appears preserved (98%-100%). Several trials prospectively validating testing biomarker integral studies, mainly
Language: Английский
Citations
4
The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown
Published: March 22, 2025
Language: Английский
Citations
0
Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6
Published: April 7, 2025
The combination of enfortumab vedotin and pembrolizumab (EVP) has been recently approved for patients with locally advanced metastatic urothelial carcinoma. This showed a higher objective response rate superior progression-free survival overall over traditional platinum-based chemotherapy in the frontline setting pivotal EV-302 trial. Despite success, subset primary refractory disease, another will develop secondary resistance time. Resistance to may include downregulation nectin-4 expression minimize antibody binding, upregulation efflux pumps against toxin, or direct by tubulin toxin. includes several methods downregulate immune system. Additionally, type histology carcinoma likely plays an important role resisting EVP. review summarizes these possible mechanisms resistance, potential biomarkers predictive overcome
Language: Английский
Citations
0
European Urology Focus, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Citations
0
JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8
Published: Dec. 1, 2024
PURPOSE Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in variety of types, with the potential to improve clinical outcomes. We evaluated ctDNA status and dynamics during surveillance part TRM outcomes both patients clear cell renal carcinoma (ccRCC) non–clear (nccRCC) treated standard-of-care immunotherapy or targeted therapy regimens. METHODS This was multicenter retrospective analysis real-world data obtained from commercial testing (Signatera, Natera, Inc) metastatic RCC. Clinical were collected on International Metastatic RCC Database Consortium (IMDC) risk category, pathologic subtype, grade. RESULTS The cohort comprised 92 (490 plasma samples) including histological subtypes (ccRCC: 79.3%; nccRCC: 14.1%; unclassified: 6.5%). Most belonged IMDC intermediate-risk category (75%, 69/92). Median follow-up 10 months (range, 4.2-25.8). assessed 56 treatment, analyzed (n = 32 patients). Serial negativity clearance correlated improved progression-free survival (PFS) compared those who became persistently positive (hazard ratio [HR], 3.2; P .012). In cohort, longitudinally experienced significantly inferior PFS (HR, 18; .00026) serially negative. CONCLUSION Collectively, we show that serial provides prognostic information undergoing surveillance, our findings demonstrate high concordance between status/dynamics subsequent
Language: Английский
Citations
3
Neurosurgery, Journal Year: 2025, Volume and Issue: unknown
Published: March 5, 2025
Glioblastoma (GBM) recurrence after surgery remains a significant clinical challenge because of limited early detection methods and effective molecular markers. This study investigates the potential dynamic tumor in situ fluid circulating DNA (TISF-ctDNA) as tool for monitoring residual disease evaluating treatment efficacy postsurgical patients with GBM. In this prospective cohort study, 75 resectable glioma were enrolled between October 2019 to June 2023. Primary tissues TISF samples collected, along cranial imaging. TISF-ctDNA was identified through targeted next-generation sequencing, positivity defined by presence one or more variants matching those primary tumors an increase ≥10 single-nucleotide across consecutive assessments. 62.2% period, indicating high prevalence disease. Patients positive showed significantly higher risk (hazard ratio 2.512, 95% CI 1.264-4.993, P = .0054). Conversion negativity post-treatment associated improved overall survival, highlighting its role response. Multivariate analysis revealed that independent predictor progression-free survival during adjuvant therapy, predictive accuracy (sensitivity 86.2%, specificity 100%). Importantly, preceded imaging signs median 71 days. no impact specific markers each subcohort (EGFR, TP53, PTEN, NF1) on observed. is promising biomarker GBM benefit. It provides insight into genomic evolution identifies who may benefit from chemotherapy. robust prognostic indicator patient outcomes marker frontline therapy.
Language: Английский
Citations
0
European Urology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Citations
2